Proactive Investors - Run By Investors For Investors

'Pivotal' year ahead for Allergy Therapeutics with key trial readouts

Nick Wykeman and Manuel Llobet from Allergy Therapeutics plc (LON:AGY) caught up with Proactive Investors following the release of their interim results.

Allergy's continued to gain market share as it heads into a ‘pivotal’ twelve months.

Interim revenues rose by 4% to £42.2mln despite the pollen season being described as ‘abnormally weak’.

Headline or first glance data from the Phase III Pollinex Quattro Birch study in Europe is expected in the second half of the year along with first results from a Grass MATA MPL Phase II trial.

 
View full AGY profile View Profile

Allergy Therapeutics PLC Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use